Offices of Optometrists (U.S.) — NAICS 621320

An investor's primer. NAICS = North American Industry Classification System, the federal code system that defines an industry for official statistics.

1. Overview

This is the business of the neighborhood eye doctor: an establishment run by an optometrist — a licensed O.D. (Doctor of Optometry) — who examines eyes, prescribes and fits glasses and contact lenses, and, increasingly, treats and monitors eye disease. It is a large, deeply fragmented health-care service industry: roughly 22,500 offices, ~148,000 workers, and about $20 billion in annual receipts, with no single firm holding even a small sliver of the market.[1][2]

The appeal is that eye care is recurring, insurance-supported, and demographically tailwinded — an aging, screen-heavy, increasingly diabetic population needs more exams over time. The catch is that the industry is not a clean, ownable "sector." The optometrist's exam is often the front door to the real profit pool, which is selling eyewear, and the practice itself is a licensed profession with tight ownership rules. So the two ways to participate look very different:

• Public-market exposure is indirect. There is no U.S.-listed pure-play "offices of optometrists." Investors reach the industry through the optical retailers that host or employ optometrists (National Vision, Warby Parker), the vertically integrated eyewear giant that also owns a major vision-insurance plan (EssilorLuxottica), and upstream product suppliers (CooperCompanies, Alcon).
• Private-market exposure is direct. The independent-practice side is an owner-operator world, now being rolled up by management-services organizations (MSOs) and private-equity (PE) platforms. Private investors can buy or back practices, lend to platforms, or own the medical-retail real estate these offices lease.

The central question is not simply "is there demand for eye care." It is whether an operator can recruit doctors, secure payer access, fill exam capacity, convert exams into eyewear sales, and scale without breaking clinical autonomy or state ownership rules.

2. What it is and how it's structured

NAICS 621320 covers establishments of practitioners holding the O.D. degree engaged in the independent practice of optometry — examining and diagnosing the visual system and prescribing and dispensing eyeglasses, contact lenses, low-vision aids, and vision therapy. Practices may stand alone or sit inside hospitals, health plans, or retail locations.[4]

It deliberately excludes several adjacent, larger money pools that a casual observer would lump into "eye care":

• Ophthalmologists — physicians (M.D.s, Doctors of Medicine, or D.O.s, Doctors of Osteopathic Medicine) who perform eye surgery and medical treatment — are counted in NAICS 621111, Offices of Physicians, not here.[4]
• Optical goods stores — retailers that sell and fit eyewear without an optometrist as the principal — are NAICS 456130, Optical Goods Retailers (renumbered from 446130 in the 2022 NAICS revision).[4]
• Eyeglass and contact-lens manufacturing sits in NAICS 339115, Ophthalmic Goods Manufacturing.

Ownership models. Optometry is a licensed profession, so practices are owned by O.D.s or operate under professional-corporation rules. The industry splits into three business models:

1. Independent private practices — the classic solo or small-group office, where the owner is doctor, retailer, and small-business operator at once.
2. Corporate / retail-affiliated optometry — an O.D. leases space beside or inside a retailer (Walmart, Costco, National Vision's America's Best, Warby Parker) and supplies the exams that feed eyewear sales. Much of this revenue books legally as retail, not "optometry."
3. MSO / private-equity platforms — roll-ups (MyEyeDr, EyeCare Partners) whose MSO centralizes billing, marketing, recruiting, purchasing, and technology, while the licensed doctor keeps clinical ownership of the professional entity.

The federal data do not break the industry down by ownership type, so any precise "X% doctor-owned" figure would be unsupported by official statistics. As a directional gauge, the American Optometric Association's (AOA) 2022 practice survey — self-reported, not a census — found most responding doctors still in private practice, with corporate-affiliated and PE-affiliated practice a meaningful and growing minority.[6]

3. How big it is

Federal statistics (our ground-truth figures):

More establishments (22,501) than firms (18,582) tells you many owners run more than one office, but only modestly so — this is a small-shop industry. Dividing receipts by firms implies roughly $1.1 million of revenue per firm (about $0.9 million per establishment). The SBA (Small Business Administration) treats an optometry office as "small" until it exceeds $9 million in receipts,[3] so essentially every establishment in the industry clears as a small business.

Two caveats matter, and both cut the same way — the official figure understates the full optometry economy:

• Employees are not optometrists. The 147,931 "paid employees" here include front-desk staff, opticians, and technicians alongside employed O.D.s. Separately, the BLS (Bureau of Labor Statistics) counts about 47,800 optometrist jobs across all settings in 2024 (median wage roughly $135,000 economy-wide, and about $128,000 for those working specifically inside optometry offices).[5] Many of those optometrists work outside 621320 — inside optical retailers (456130) or physician and hospital groups (621111) — so this code captures only the standalone-office slice of U.S. optometry.
• The whole "eye-care wallet" is bigger. Because so much optometry happens inside retail chains and PE platforms whose revenue books as retail, private data vendors that measure the broader optometrist market put recent revenue closer to $23 billion while still describing the field as highly fragmented, with no company much above ~5% share.[10] Treat the $20.1 billion Census figure as the conservative, definition-strict number.

The federal extract contains no industry-level margin, EBITDA, exam volume, payer mix, or capacity-utilization figure, and mixes vintages (receipts are 2022; payroll and employment are 2023), so it should not be used to back out an industry margin. The practice-level economics in Section 5 come from trade sources, clearly flagged as such.

4. The investable universe

There is no U.S.-listed pure-play "offices of optometrists." Public exposure comes through the companies that surround the exam chair — retailers, the vertically integrated eyewear giant, and product suppliers.

Major private / non-listed owners and platforms:

• MyEyeDr. (parent: Capital Vision Services) — a large MSO-backed platform supporting affiliated independent O.D.s; it describes a network of 900+ practices and 1,500+ optometrists. Goldman Sachs Merchant Banking acquired Capital Vision Services in 2019 (from Altas Partners and Caisse de dépôt et placement du Québec, or CDPQ) at a reported enterprise value near $2.7 billion.[19]
• EyeCare Partners — a Partners Group-backed, clinically integrated network spanning optometry and ophthalmology; its Clarkson Eyecare brand alone lists 700+ locations across 18 states.[20]
• VSP Vision — the largest U.S. vision-benefits organization (originally Vision Service Plan), a not-for-profit that both administers vision insurance and owns retail (Visionworks), and which completed its acquisition of Eyemart Express in 2025. It shapes practice economics as a payer, not a stock.[21]
• Total Eye Care Partners and dozens of regional roll-ups; plus the surviving independents, still central where doctor continuity and community relationships matter.

Bottom line for public-market investors: you are mostly buying retail unit economics and eyewear margins, with optometry as the traffic driver — not a book of doctors' fees.

5. How the money works

An optometry office is a hybrid: part health-care service, part specialty retailer. Revenue comes in two streams, and the second is where much of the margin lives. (The splits and ratios below are trade-source benchmarks,[11] not federal data — the official file carries none.)

• Professional fees (~55% of revenue): the eye exam and any medical treatment or monitoring. Reimbursement varies sharply by how the visit is billed: a routine vision-plan exam may pay well under $100, while the same visit billed as medical eye care (e.g., a diabetic retinal check) can pay appreciably more — a core reason practices push into medical optometry.[11]
• Dispensing / optical (>40% of revenue): selling the glasses and contacts the exam prescribes. Eyewear typically carries 50–70% gross margins; contact lenses roughly 30–50%.[11]

The operating levers a practice actually manages:

• Capture rate — the share of exam patients who buy their eyewear on-site (industry average around 60%; well-run optical departments hit 75%+). Each point of capture is worth real money to a small practice.[11]
• Revenue per exam — lifted by premium lenses and coatings and by billing medical eye care to medical insurance rather than thin routine-vision plans.
• Chair time / doctor utilization — exams per day per doctor; the exam is the constrained resource that generates the downstream optical sale.
• Payer mix — vision plans (VSP, EyeMed) drive patient volume but reimburse eyewear thinly, so many independents cap the worst-paying plans and lean on cash-pay and medical billing.

At federal scale, receipts imply a typical practice on the order of $1 million in annual revenue with ~7–8 employees at one site. Trade sources put net margins commonly in the ~25–40%-of-revenue range after cost of goods and operating expenses — attractive economics, and a reason owner-optometrists out-earn employed ones.[6][11] That owner premium and steady cash flow are exactly what PE buyers pay for.

For public operators, the metrics that matter are comparable/same-store sales, exam volume and slots filled, revenue per patient and optical conversion, eyewear gross margin and contact-lens mix, doctor productivity/vacancy/retention, payer mix and reimbursement, new-store payback, and net debt to operating cash flow. For private buyers, the equivalents are normalized owner-doctor compensation, medical-vs.-optical revenue split, payer-contract economics, patient retention, inventory aging, lease costs, doctor coverage, and cash conversion.

The industry is partly defensive: routine exams and medically necessary care recur. Eyewear upgrades, premium frames, and some contact-lens purchases are more sensitive to consumer confidence.

6. What drives demand

Demand is non-cyclical and slowly growing, driven by biology and demographics more than the economy:

• Aging. Presbyopia, cataracts, glaucoma, and macular degeneration rise sharply with age, increasing the need for regular exams and follow-up care.[18]
• Chronic disease. Diabetes and hypertension create recurring demand for detection, monitoring, and referral of eye complications; optometrists frequently catch systemic disease through the eye, pushing optometry deeper into higher-reimbursing medical care.[18]
• Refractive error. Myopia (nearsightedness), presbyopia, astigmatism, and hyperopia sustain glasses and contact-lens demand. Myopia prevalence in particular is climbing with screen time and indoor childhoods.[18]
• Insurance and employer benefits. Vision coverage (employer plans, Medicaid pediatric coverage) lowers out-of-pocket cost and directs traffic to in-network providers, converting latent need into paid visits.
• Medical scope expansion. Where state law permits, optometrists manage more disease and relieve scarce ophthalmology capacity, adding billable medical services.[17]
• Workforce trend. The BLS projects optometrist employment to grow 8% from 2024 to 2034 (roughly 2,400 openings per year), faster than the average occupation.[5]

The principal near-term constraint is clinician supply: an office with strong demand but no optometrist coverage cannot monetize its exam rooms, optical staff, or inventory. The offset on the retail side is cyclicality — routine exams and new frames are deferrable in a downturn, and growth is measured in low single digits per year, not a boom.

7. Regulation

Optometry is one of the most regulation-shaped small industries because it combines health care, retail, insurance, and prescription products.

• State licensure and scope of practice. State optometry boards license O.D.s and define what they may do — which drugs they can prescribe, whether they can perform certain laser or minor procedures, and supervision/referral rules. Scope varies widely and is a continuous state-by-state fight between optometrists and ophthalmologists; federal antitrust agencies have at times urged states to expand optometric scope on competition grounds. Each expansion adds billable medical services to the model.[17]
• FTC (Federal Trade Commission) prescription-release rules. The Eyeglass Rule requires prescribers to hand patients their eyeglass prescription after a refraction, free of charge.[13] The Contact Lens Rule, implementing the Fairness to Contact Lens Consumers Act, forces prescribers to release the contact-lens prescription, honor a minimum one-year validity, and verify prescriptions for third-party sellers.[14] These rules deliberately break the tie between the exam and the eyewear sale — letting patients buy online (1-800 Contacts, Warby Parker, retailers) — and are a structural headwind to optical capture rate.
• FDA (Food and Drug Administration). Contact lenses are regulated as medical devices, from manufacture through sale.[15]
• Medicare. Original Medicare generally does not cover routine eye exams, eyeglasses, or contact lenses, but it does cover certain disease-related services and glaucoma screening for eligible high-risk patients — reinforcing the shift toward medical optometry.[16]
• Corporate practice of medicine (CPOM). State CPOM rules may restrict non-physician ownership or control of clinical practices. Investors typically use an MSO plus a doctor-owned professional entity, but the exact structure must be vetted state by state. Policy risk here is live: Oregon enacted a first-in-the-nation law aimed at curbing corporate takeovers of medical practices and tightening MSO standards, which other states may copy.[17]
• Other compliance. HIPAA (Health Insurance Portability and Accountability Act) patient-data rules, anti-kickback and false-claims law on the medical-billing side, professional-liability/malpractice, cybersecurity, and advertising rules all apply.

8. Competitive dynamics and consolidation

The federal concentration data confirm an unusually fragmented industry: the four largest firms hold just 7.8% of receipts, the top eight 10.1%, the top twenty 13.3%, and the top fifty only 16.4%.[2] The Census-reported Herfindahl-Hirschman Index (HHI) — a standard concentration gauge on a 0–10,000 scale, where regulators treat anything below 1,500 as "unconcentrated" — is a rock-bottom 21.7, fully consistent with that CR4 of 7.8%.[2] Thousands of independent doctors compete with a handful of national chains.

That fragmentation is the entire thesis for consolidators. Competition is fundamentally local — patients choose on doctor reputation, location, appointment availability, insurance acceptance, price, and frame selection — but scale can improve purchasing and lab economics, marketing efficiency, recruiting and scheduling, claims administration, technology, and payer-network access. Scale does not automatically create clinical quality or pricing power. The structure is now a three-way contest:

1. National optical retailers (National Vision, Warby Parker, EssilorLuxottica's LensCrafters/Target Optical/Pearle) competing on price, convenience, and brand.
2. MSO / private-equity roll-ups (MyEyeDr, EyeCare Partners, and peers) buying independents to build regional density and negotiate better payer and supplier terms.
3. Surviving independents, competing on relationship, medical-optometry depth, and premium service.

Deal pricing (a private-market signal): standard independent practices have traded around 3–6x EBITDA (earnings before interest, taxes, depreciation, and amortization), with larger "platform-ready" practices at 6–8x and full platforms in the low-to-mid teens. Multiples compressed somewhat from the 2020–2022 low-rate peak as financing got more expensive, and PE activity has shifted from forming new platforms toward bolt-on add-ons.[12] The real value-creation test is doctor and patient retention, not the raw number of acquisitions closed.

Vertical integration is the other structural force: EssilorLuxottica manufactures the lenses and frames, owns the stores, and owns EyeMed — collecting the insurance premium, the retail margin, and the manufacturing profit from a single pair of glasses.[9] That lowers cost and improves customer acquisition, but can create conflicts over product sourcing, referrals, and payer access.

9. Risks

• Disintermediation of eyewear. Online sellers plus the FTC prescription-release rules keep chipping at the optical margin that funds the practice. If capture rates fall, the whole model weakens.
• Reimbursement / vision-plan squeeze. VSP and EyeMed drive volume but reimburse eyewear thinly and rarely raise rates; insurers can narrow networks or redesign benefits. Heavy plan dependence caps profitability.
• Clinician scarcity. Optometrist supply grows only modestly (~8% job growth 2024–2034); doctor vacancies leave fixed rent and staff underused, and wage inflation for doctors is a real cost retail hosts have flagged.[5]
• PE over-leverage and integration risk. Roll-ups built with cheap debt face refinancing at higher rates; acquisitions can fail through doctor departures, patient attrition, incompatible systems, or loss of local trust.
• Regulatory fragmentation and reversals. State-by-state scope and CPOM rules raise compliance cost and can delay deals; optometry's medical growth depends on winning state scope fights against organized ophthalmology, and setbacks cap the higher-margin line.
• Clinical and legal liability. Misdiagnosis, delayed referral, contact-lens complications, billing violations, and malpractice claims can damage a platform.
• Discretionary/cyclical eyewear. Frames and premium lenses are deferrable; a consumer pullback hits ticket size even if exam counts hold.

10. How to invest and the outlook

Public routes. The cleanest listed operating exposure is the value-retail model — National Vision (EYE), whose America's Best pairs low-cost exams with in-store O.D.s; watch comparable-store sales, the doctor-staffing/cost line, and the post-Walmart transition.[7] Warby Parker (WRBY) is the growth/brand bet, layering eye exams onto its stores and pushing insurance-backed orders, though exams are still a small share of revenue.[8] EssilorLuxottica (EL / ESLOY) is the diversified, vertically integrated way to own the whole eyewear-and-insurance stack, with U.S. optometry only one slice.[9] CooperCompanies (COO) and Alcon (ALC) offer upstream product exposure rather than practice ownership.

Useful public-market diligence questions: Are exam volumes and comparable sales growing organically? Is growth from patients, pricing, acquisitions, or new stores? Are optometrist vacancies capping revenue? Is medical-care revenue outgrowing optical retail? Are payer contracts improving or compressing margins? Are acquisitions earning acceptable cash returns, and is leverage reasonable against recurring cash flow?

Private routes. This is where most of the actual "offices of optometrists" economics live: buying or backing independent practices, investing in or lending to MSO/PE platforms (MyEyeDr, EyeCare Partners, Total Eye Care Partners), or owning the small-format medical-retail real estate these offices lease. Underwrite the practice, the doctor relationship, and the legal structure separately — patient and payer retention, doctor compensation and clinical autonomy, state CPOM compliance, lease terms, optical inventory, billing audits, and the seller's post-deal role. Mid-single-digit EBITDA multiples for independents remain the reference point.[12]

Forward-looking judgment. The demand backdrop is dependable and slowly rising — aging eyes, worsening myopia, and more medical eye disease should keep exam volumes growing through the next decade, and optometry's push into medical care is the most attractive margin lever. The structural tension is between that steady clinical demand and a persistently squeezed retail margin, pressured by online eyewear and thin vision-plan reimbursement. Expect continued consolidation, with the winners being operators who combine local clinical trust with disciplined payer management and who lift medical billing and capture rate rather than relying on frame markups alone. For public investors the bet is largely on retail execution; for private investors it is on buying durable local practices — at sensible multiples, with a clean legal structure — before the roll-ups do.

---

Sources

1. U.S. Census Bureau. "County Business Patterns, 2023 — NAICS 621320 Offices of Optometrists" (establishments, employment, annual and Q1 payroll). https://www.census.gov/programs-surveys/cbp.html
2. U.S. Census Bureau. "2022 Economic Census — Concentration of Largest Firms, NAICS 621320" (receipts, firm count, CR4/CR8/CR20/CR50, HHI). https://data.census.gov/table/ECNSIZE2022.EC2200SIZECONCEN
3. U.S. Small Business Administration. "Table of Small Business Size Standards (NAICS 621320)," 2023. https://www.sba.gov/document/support-table-size-standards
4. U.S. Census Bureau. "NAICS 2022 — 621320 Offices of Optometrists (definition and exclusions)." https://www.census.gov/naics/?input=621320&year=2022
5. U.S. Bureau of Labor Statistics. "Occupational Outlook Handbook: Optometrists" (2024 employment ~47,800, median wage, 8% projected growth 2024–2034) and OEWS industry wage detail. https://www.bls.gov/ooh/healthcare/optometrists.htm
6. American Optometric Association. "2022 AOA Survey of Optometric Practice" (ownership mix and owner income premium; self-reported survey). https://www.ferris.edu/optometry/pdfs-docs/2022_AOA_Income.pdf
7. National Vision Holdings, Inc. "Form 10-K, Fiscal Year 2025" (store count ~1,250, revenue, host-doctor model, Walmart wind-down). https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001710155&type=10-K
8. Warby Parker Inc. "Form 10-K, Fiscal Year 2025" and FY2024 results (323 stores/285 with exams, ~6.4% exam revenue, 2024 revenue ~$771M). https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001504776&type=10-K
9. EssilorLuxottica. "2025 Annual Report" (brands — LensCrafters, Pearle Vision, Target Optical, Sunglass Hut — and EyeMed vision insurance). https://www.essilorluxottica.com/en/investors/
10. IBISWorld. "Optometrists in the US — Industry Report" (broader market size ~$23B, fragmentation). https://www.ibisworld.com/united-states/industry/optometrists/1560/
11. Review of Optometric Business / BCAT. "Optometry Practice Finances: Revenue & Profit Benchmarks" (revenue split, capture rate, eyewear/contact margins, net margin). https://mybcat.com/blog/optometry-practice-finances/
12. Physician Growth Partners. "State of Eye Care Private Equity and Optometry M&A Multiples," 2025. https://physiciangrowthpartners.com/white-paper/state-of-eye-care-private-equity-q1-2025/
13. U.S. Federal Trade Commission. "Complying with the Eyeglass Rule." https://www.ftc.gov/business-guidance/resources/complying-eyeglass-rule
14. U.S. Federal Trade Commission. "Contact Lens Rule (16 CFR Part 315) — implementing the Fairness to Contact Lens Consumers Act." https://www.ftc.gov/business-guidance/resources/contact-lens-rule-guide-prescribers-sellers
15. U.S. Food and Drug Administration. "Buying Contact Lenses" (contact lenses regulated as medical devices). https://www.fda.gov/medical-devices/contact-lenses/buying-contact-lenses
16. Centers for Medicare & Medicaid Services. "Medicare Vision Services" (coverage of disease-related eye care; routine exams/eyewear generally excluded). https://www.cms.gov/outreach-and-education/medicare-learning-network-mln/mlnproducts
17. U.S. Federal Trade Commission / DOJ and American Medical Association. Scope-of-practice competition statements; "Behind Oregon's First-in-Nation Law Curbing Corporate Medicine," 2026. https://www.ama-assn.org/practice-management/private-practices/behind-oregons-first-in-nation-law-curbing-corporate-medicine
18. Centers for Disease Control and Prevention. "About Common Eye Disorders and Diseases." https://www.cdc.gov/vision-health/about-eye-disorders/index.html
19. Altas Partners / Optometry Times. "Goldman Sachs Merchant Banking acquires Capital Vision Services (MyEyeDr.)," 2019; MyEyeDr. network profile (900+ practices, 1,500+ optometrists). https://www.altas.com/news/altas-partners-announces-agreement-to-sell-capital-vision-services
20. Clarkson Eyecare / Partners Group. "EyeCare Partners — About / network profile (700+ locations, 18 states)." https://www.clarksoneyecare.com/about-us
21. VSP Vision. "VSP Vision Completes Eyemart Express Acquisition," 2025 (largest not-for-profit vision-benefits organization; owns Visionworks). https://www.vspvision.com/newsroom/company-news/company-announcements/vsp-vision-completes-eyemart-express-acquisition